I definitely would not dismiss what the company is doing here with regards to IHL-675A.
Let me preface everything I say here with the fact that I'm not a medico but I've done some reading on the subject.
Side effects of Hydroxychloroquine include heart failure, arrhythmia and possibly others - I'm sure you've read all about that.
IHL's objective is to
combine Hydroxychloroquine and
CBD together with APIs to reduce the dosage of Hydroxychloroquine and so this should potentially reduce the risk of major side effects.
Apart from that, it is becoming obvious that the biggest killer is not the virus itself (COVID-19) but it's the immune system going haywire and basically attacking the body in what's labelled a "cytokine storm" that is the major problem here. We all know that CBD is a potent anti-inflammatory and so the rationale is that this will nip the cytokine storm in the bud before the immune system goes out of control - it regulates the immune response if you like.
Dr. Sud will have looked at this very closely before committing to it, trust me, the guy knows what he's doing.
Interesting article on the cytokine storm / COVID-19:-
https://www.abc.net.au/news/health/2020-04-25/coronavirus-covid-immune-response-causes-harm/12176872
